Dynamics of CYP51: implications for function and inhibitor design.
Xiaofeng Yu1, Vlad Cojocaru, Ghulam Mustafa
1Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies, Heidelberg, Germany.
Journal of Molecular Recognition : JMR
|January 21, 2015
Summary
Sterol 14α-demethylase (CYP51) dynamics were simulated in Trypanosoma brucei to aid antiparasitic drug design. Simulations revealed key ligand access and egress pathways, offering insights for developing selective CYP51 inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Parasitology
Background:
- Sterol 14α-demethylase (CYP51) is crucial in all life forms, located in the endoplasmic reticulum membrane in eukaryotes.
- Selective inhibitors of trypanosomal CYP51 show promise for treating Chagas disease, with potential for targeted drug design due to CYP51's structural rigidity.
Purpose of the Study:
- To investigate the dynamics of membrane-bound Trypanosoma brucei CYP51 using molecular dynamics simulations.
- To compare the dynamic properties of T. brucei CYP51 with human CYP51, CYP2C9, and CYP2E1.
Main Methods:
- Construction of a model for membrane-bound T. brucei CYP51.
- Performing molecular dynamics simulations on both membrane-bound and soluble forms of T. brucei CYP51.
- Comparative analysis of T. brucei CYP51 dynamics against human CYP orthologs.
Main Results:
- CYP51 enzymes exhibit low active site mobility, with overall mobility comparable to other CYPs.
- Pathway 2f identified as the primary ligand access tunnel; pathways 2f and S serve as egress tunnels.
- CYP51 shows increased mobility at ligand tunnel entrances, facilitating large sterol ligand passage, and unique heme propionate conformations affecting the water tunnel.
Conclusions:
- Molecular dynamics simulations provide crucial insights into CYP51 enzyme dynamics, complementing experimental data.
- The identified dynamic features and ligand pathways of T. brucei CYP51 are vital for designing effective and selective antiparasitic drugs.
- Understanding CYP51 dynamics aids in developing novel therapeutics against parasitic infections by targeting essential enzymes.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
273
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
273
01:30Enzyme Inhibition
95.4K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
95.4K
01:25Pharmacokinetics: Drug–Drug Interactions
766
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
766
01:16Protein-Drug Binding: Mechanism and Kinetics
2.2K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.2K
02:34Enzymes
97.7K
Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
97.7K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132